programmed cell death-1 (PD-1) antibody, nivolumab, has been widely used as an ICI. ICIs have a unique adverse event known as immunerelated adverse event (irAE) which manifest most frequently as a skin disorder, and very rarely as a renal disorder.
ment of lung adenocarcinoma with no driver mutation and received immune checkpoint inhibitor; nivolumab. The best clinical response was partial response with nivolumab monotherapy, however, AKI which was likely to be associated with irAE, developed after 26 cycles of it; Serum creatinine level was elevated to 4.61 mg/dL. Administration of corticosteroid recovered the kidney function and nivolumab monotherapy was rechallenged, leading to the recurrence of severe AKI (serum creatinine level: 8.05 mg/dL) which required haemodialysis. Renal biopsy was performed and it showed acute tubulointerstitial nephritis with infiltrating neutrophils and lymphocytes.
Conclusion: Though the incidence of AKI induced by ICIs is less than that of other organ dysfunction, patients may develop severe AKI requiring haemodialysis. ICIs induced-AKI is characterized by late onset after administration, and in our case, it was the longest duration among the reported cases. It is speculated that ICIs re-program the immune system, leading to the loss of tolerance to endogenous and exogenous antigens, which is different from the mechanism underlying AKI induced by other medications. Therefore, re-challenging ICIs after recovery of the renal function should be tried. Nevertheless, prolonged follow up is needed to detect the late recurrence of severe AKI as reported in our case. Background and Aims: Lung cancer is one of world's deadliest cancer, with 1.8 million new cases and 1.59 million deaths caused by lung cancer in 2012. Lung cancer is also known to be more prevalent in males than in females. Although active smoking is already known to have causative relationship with lung cancer, about 25% of lung cancer cases worldwide are not associated with active smoking. In Southeast Asia, approximately 50% of lung cancer cases are thought to have nothing to do with active smoking.
Methods: This study is a case-control study with 45 subjects in total: 27 with lung cancer and 18 with no lung cancer who enrolled to Persahabatan National Hospital in July 2016 -January 2017. The data regarding demographics, smoking status, exposure to environmental tobacco smoke, family history of cancer, history of tuberculosis, and exposure to indoor air pollution of each patient were obtained. Descriptive statistics, Chi square hypothesis test, and logistic regression hypothesis test were used for analysis.
Results:
Results from bivariate analysis showed that environmental tobacco smoke (ETS) (OR = 6.914; CI 1.78-26,853) and family history of cancer (OR = 8.5; CI 0.971-74.424) were associated with increased risk of lung cancer in male never-smokers, while other risk factors were not found to have been associated with lung cancer in male never-smokers. Multivariate analysis showed both ETS and family history of lung cancer were associated with risk of lung cancer in male never-smokers, with ETS being the most associated factor having individuals with exposure to ETS to have 8,479 more likely odds of developing lung cancer.
Conclusion:
There is a significant association between exposure to environmental tobacco smoke (ETS) and family history of cancer with increased risk of lung cancer in male never-smokers, with ETS being the most associated factor with the increased odds of developing lung cancer in male never-smokers. 
Methods:
The patient was a 64-year-old woman who was found to have right lung segment S4 ground-glass nodule (GGN) on chest computed tomography (CT) following opacification detected on routine chest X-ray. Follow-up CT revealed a 42-mm GGN nodule with a 26-mm nodule (S6) and a 20-mm GGN (S10).
Results: Histopathology of resected specimens from the right middle and lower lobes revealed all three nodules were adenocarcinoma. Four EGFR mutations were detected; no three tumours had the same mutations. Background and Aims: Mycoplasm pneumoniae is the main pathogen in upper respiratory tract infection among children, and the morbidity is also high. In addition to causing respiratory mucosa, it can act as an allergen to cause airway hyperresponsiveness, result in long-range cough, even trigger or develop asthma. Leukotriene receptor antagonist montelukast can block Mycoplasma pheumoniae that stimulates the inflammatory response of the repiratory tract as an allergen after infection, and lower airwy hyperresponsiveness Methods: Totally 100 children infected with Mycoplasma pneumoniae from June 2015 to June 2016 in paediatrics department of our hospital were selected to randomly assign into the observation group and the control group. Both groups took conventional anti-mycoplasma therapy,
